NSABP [hcro]
study trial [resa]
Tamoxifen [orch, phsu]
Raloxifene [orch, phsu]
In [qnco]
Study [mnob]
Tamoxifen [orch, phsu]
Raloxifene [orch, phsu]
Study [mnob]
Tamoxifen [orch, phsu]
Raloxifene [orch, phsu]
Trial [resa]
postmenopausal [tmco]
Women [popg]
Increased [qnco]
Breast Cancer [neop]
Received [qlco]
Oral [spco]
Tamoxifen [orch, phsu]
mg day [qnco]
Raloxifene [orch, phsu]
mg day [qnco]
Equal [qlco]
Cases [ftcn]
Invasive Breast Cancer [neop]
Women [popg]
Assigned [ftcn]
Tamoxifen [orch, phsu]
Raloxifene [orch, phsu]
Few [qnco]
Cases [ftcn]
Non-invasive [ftcn]
Breast Cancer [neop]
Tamoxifen [orch, phsu]
Group [idcn]
Raloxifene [orch, phsu]
Group [idcn]
Risk Ratio [qnco]
Cases [ftcn]
Uterine Cancer [neop]
Tamoxifen [orch, phsu]
Raloxifene [orch, phsu]
Risk Ratio [qnco]
Cl - [elii]
Thromboembolic events [patf]
Occurred [acty]
Often [tmco]
Raloxifene [orch, phsu]
Group [idcn]
Risk Ratio [qnco]
Cl - [elii]
Few [qnco]
Cataracts [anab]
cataract surgeries [topp]
Women [popg]
Take [hlca]
Raloxifene [orch, phsu]
Risk Ratio [qnco]
Cl - [elii]
study trial [resa]
Tamoxifen [orch, phsu]
Raloxifene [orch, phsu]
Raloxifene [orch, phsu]
effective [qlco]
Tamoxifen [orch, phsu]
Reducing [qlco]
Invasive Breast Cancer [neop]
Low Risk [fndg]
adverse events [fndg]
High Risk [qlco]
Non-invasive [ftcn]
Breast Cancer [neop]
Fractures [inpo]
ischaemic heart disease [dsyn]
Stroke [dsyn]
Drugs [phsu]
